Gardyszewska Agnieszka, Czajkowski Krzysztof
II Katedra i Klinika Poroznictwa i Ginekologii Warszawskiego Uniwersytetu Medycznego, Polska.
Ginekol Pol. 2012 Dec;83(12):950-2.
Intrauterine device is a popular cost-effective method of contraception known worldwide. It is extremely effective, with pregnancy rates comparable to tubal ligation (5-year cumulative rate varying from 0.5 to 1.1). LNG-IUS increases in popularity and may be used as the method of choice for adults because it offers non-contraceptive benefits: slight menstrual bleeding, decreased number of incidents of dysmenorrhea, and reduced pain associated with endometriosis. The levonorgestrel-releasing intrauterine system (LNG-IUS) provides a release rate of 20 microg/24 h of levonorgestrel. The hormone released from the intrauterine device causes some systemic changes, however local effects, such as glandular atrophy and stromal decidualization, in addition to foreign body reaction, are dominant. According to the Food and Drug Administration regulations, category X was assigned to LNG. The use of the product is contraindicated in women who are or may become pregnant. We report a case of a 30-year old woman who has already been pregnant before the insertion of a levonorgestrel -releasing intrauterine system (LNG-IUS). The patient was lactating after the previous pregnancy the first menstruation had not appeared yet. The patient planned to have the IUD inserted but she missed her appointed visits twice. The third visit took place 8 weeks postpartum. During that visit, the doctor asked her about the possibility of being pregnant, but the patient denied. The gynecologist inserted the intrauterine device and performed transvaginal ultrasound examination. The location of LNG-IUS was proper and there was no gestation sac in the uterine cavity. After the next six weeks, transvaginal ultrasonography and manual examination showed an intrauterine pregnancy at 8 weeks of gestation. The intrauterine device was not detectable in the uterine cavity by ultrasound, and the IUD strings were not visualized in the vagina. It was impossible to remove the device without causing miscarriage. Other risks during pregnancy were connected with potential masculinisation of the fetus by levonorgestrel, premature delivery and preterm rupture of the membranes. The pregnancy progressed normally and the delivery was uncomplicated. A female infant was born without congenital abnormalities. The pediatrician did not find any indices of infection. The IUD was found in fetal membranes. The postpartum recovery was uneventful. This case report demonstrates that a healthy infant can be delivered at term with an IUS in situ, probably without causing any abnormalities. Due to that fact that adverse effects of fetal exposure to the LNG-IUS have not been yet established, the exclusion of pregnancy before IUD insertion is strictly indicated.
宫内节育器是一种广为人知且经济有效的避孕方法。它极其有效,妊娠率与输卵管结扎相当(5年累积率在0.5%至1.1%之间)。左炔诺孕酮宫内缓释系统(LNG-IUS)越来越受欢迎,可作为成年人的首选方法,因为它具有非避孕益处:月经量轻微减少、痛经发生率降低以及与子宫内膜异位症相关的疼痛减轻。左炔诺孕酮宫内缓释系统(LNG-IUS)的左炔诺孕酮释放速率为20微克/24小时。宫内节育器释放的激素会引起一些全身变化,然而,局部效应,如腺体萎缩和间质蜕膜化,以及异物反应,更为显著。根据美国食品药品监督管理局的规定,LNG被归类为X类。该产品禁止用于已怀孕或可能怀孕的女性。我们报告一例30岁女性的病例,她在放置左炔诺孕酮宫内缓释系统(LNG-IUS)之前已经怀孕。患者在前次妊娠后正在哺乳,尚未出现首次月经。患者计划放置宫内节育器,但她两次错过预约就诊。第三次就诊在产后8周进行。在那次就诊时,医生询问她是否有可能怀孕,患者予以否认。妇科医生放置了宫内节育器并进行了经阴道超声检查。LNG-IUS位置合适,宫腔内未见妊娠囊。六周后,经阴道超声检查和体格检查显示妊娠8周,为宫内妊娠。超声在宫腔内未检测到宫内节育器,阴道内也未见到节育器尾丝。在不导致流产的情况下无法取出节育器。孕期的其他风险与左炔诺孕酮可能导致胎儿男性化、早产和胎膜早破有关。妊娠进展正常,分娩顺利。一名女婴出生,无先天性异常。儿科医生未发现任何感染迹象。宫内节育器在胎膜中被发现。产后恢复顺利。本病例报告表明,宫内节育器在位时可足月分娩出健康婴儿,可能不会引起任何异常。由于胎儿接触LNG-IUS的不良影响尚未确定,因此在放置宫内节育器前严格要求排除妊娠。